- Home
- MYNZ vs SILO Comparison
MYNZ vs SILO Comparison
Compare MYNZ & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- SILO
- Stock Information
- Founded
- MYNZ 2021
- SILO 2010
- Country
- MYNZ Germany
- SILO United States
- Employees
- MYNZ N/A
- SILO N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- MYNZ Health Care
- SILO Consumer Discretionary
- Exchange
- MYNZ Nasdaq
- SILO Nasdaq
- Market Cap
- MYNZ 10.5M
- SILO 8.8M
- IPO Year
- MYNZ 2021
- SILO N/A
- Fundamental
- Price
- MYNZ $3.44
- SILO $1.08
- Analyst Decision
- MYNZ Buy
- SILO
- Analyst Count
- MYNZ 3
- SILO 0
- Target Price
- MYNZ $14.00
- SILO N/A
- AVG Volume (30 Days)
- MYNZ 177.3K
- SILO 139.6K
- Earning Date
- MYNZ 04-15-2025
- SILO 05-12-2025
- Dividend Yield
- MYNZ N/A
- SILO N/A
- EPS Growth
- MYNZ N/A
- SILO N/A
- EPS
- MYNZ N/A
- SILO N/A
- Revenue
- MYNZ $893,991.00
- SILO $72,102.00
- Revenue This Year
- MYNZ $20.94
- SILO $1.86
- Revenue Next Year
- MYNZ $18.01
- SILO N/A
- P/E Ratio
- MYNZ N/A
- SILO N/A
- Revenue Growth
- MYNZ N/A
- SILO N/A
- 52 Week Low
- MYNZ $0.18
- SILO $0.77
- 52 Week High
- MYNZ $8.20
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- MYNZ 37.70
- SILO 28.08
- Support Level
- MYNZ $2.72
- SILO $1.20
- Resistance Level
- MYNZ $5.34
- SILO $1.39
- Average True Range (ATR)
- MYNZ 0.55
- SILO 0.09
- MACD
- MYNZ -0.12
- SILO -0.02
- Stochastic Oscillator
- MYNZ 27.48
- SILO 0.00
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.